Literature DB >> 8257183

Decline in hepatitis B infection in sickle cell anaemia and beta thalassaemia major.

I al-Fawaz1, S Ramia.   

Abstract

Seventy five Saudi children, 55 with sickle cell anaemia and 20 with beta thalassaemia major, who were negative for all hepatitis B virus (HBV) markers five years ago were recently investigated for exposure to HBV and hepatitis C virus (HCV) infection. Of the 55 patients with sickle cell anaemia and 20 with beta thalassaemia major, 20 and five patients respectively had been vaccinated against HBV earlier and all of them still had protective antibody (anti-HBs 42-96 IU) 3-5 years after vaccination and there was no vaccine failure. Among the non-vaccinated children the exposure rates to HBV were 14.3% among those with sickle cell anaemia and 26.7% among those with beta thalassaemia and this was not statistically significant when compared with the exposure rate to HBV among the general paediatric population (20.1%). Anti-HCV positivity among those with beta thalassaemia major and sickle cell anaemia was 70% and 18.2%, respectively, and this was significantly higher than anti-HCV positivity among the control group (0.8%). Anti-HCV positivity was directly related to the amount of blood transfused and to the duration of transfusion. The results of the study show that although the exposure rates to HBV among patients with sickle cell anaemia and beta thalassaemia major were not significantly different than that among the general paediatric population, infection with HBV still takes place among non-vaccinated patients despite strict precautionary measures taken. Hence early vaccination against HBV would probably be the only effective way of controlling HBV infection. For HCV infection, and because a vaccine against HCV is still not available, preventive measures such as blood screening for anti-HCV before transfusion and stringent infection control measures are crucial steps to be implemented for the control of spread of HCV among these groups of patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8257183      PMCID: PMC1029626          DOI: 10.1136/adc.69.5.594

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  22 in total

1.  The prevalence of hepatitis C virus antibodies among hemodialysis patients.

Authors:  J B Zeldis; T A Depner; I K Kuramoto; R G Gish; P V Holland
Journal:  Ann Intern Med       Date:  1990-06-15       Impact factor: 25.391

2.  Surrogate markers are not useful for identification of HCV carriers in chronic hemodialysis patients.

Authors:  M Willems; G de Jong; H Moshage; L Verresen; P Goubau; J Desmyter; S H Yap
Journal:  J Med Virol       Date:  1991-12       Impact factor: 2.327

3.  Prevalence and significance of antibodies to hepatitis C virus among Saudi haemodialysis patients.

Authors:  E A Ayoola; S Huraib; M Arif; F Z al-Faleh; R al-Rashed; S Ramia; I A al-Mofleh; H Abu-Aisha
Journal:  J Med Virol       Date:  1991-11       Impact factor: 2.327

4.  Intrafamilial clustering of hepatitis B virus (HBV) infection: study of 10 Saudi families.

Authors:  S Ramia
Journal:  Ann Trop Med Parasitol       Date:  1990-12

5.  Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV).

Authors:  U Hopf; B Möller; D Küther; R Stemerowicz; H Lobeck; A Lüdtke-Handjery; E Walter; H E Blum; M Roggendorf; F Deinhardt
Journal:  J Hepatol       Date:  1990-01       Impact factor: 25.083

6.  Hepatitis B surface antigen in Nigerian children with sickle cell anaemia.

Authors:  W N Kaine; G O Okafor
Journal:  J Trop Pediatr       Date:  1983-02       Impact factor: 1.165

7.  Diagnostic value of anti-HBc IgM in high HBV prevalence areas.

Authors:  G Papaevangelou; A Roumeliotou-Karayannis; N Tassopoulos; P Stathopoulou
Journal:  J Med Virol       Date:  1984       Impact factor: 2.327

8.  Integration of hepatitis B vaccine into the expanded program on immunization: The Saudi Arabian experience.

Authors:  F Z Al-Faleh; E A Ayoola; M Al-Jeffry; M Arif; R S Al-Rashed; S Ramia
Journal:  Ann Saudi Med       Date:  1993-05       Impact factor: 1.526

9.  Lack of protective immunity against reinfection with hepatitis C virus.

Authors:  P Farci; H J Alter; S Govindarajan; D C Wong; R Engle; R R Lesniewski; I K Mushahwar; S M Desai; R H Miller; N Ogata
Journal:  Science       Date:  1992-10-02       Impact factor: 47.728

10.  An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.

Authors:  G Kuo; Q L Choo; H J Alter; G L Gitnick; A G Redeker; R H Purcell; T Miyamura; J L Dienstag; M J Alter; C E Stevens
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

View more
  5 in total

Review 1.  Hepatitis B, C & D viral markers in multitransfused thalassemic children: long-term complications and present management.

Authors:  V P Choudhry; S K Acharya
Journal:  Indian J Pediatr       Date:  1995 Nov-Dec       Impact factor: 1.967

Review 2.  Potential for human immunodeficiency virus parenteral transmission in the Middle East and North Africa: an analysis using hepatitis C virus as a proxy biomarker.

Authors:  Yousra A Mohamoud; F DeWolfe Miller; Laith J Abu-Raddad
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

3.  Hepatitis C and blood transfusion among children attending the Sickle Cell Clinic at Mulago Hospital, Uganda.

Authors:  S O M Namasopo; C Ndugwa; J K Tumwine
Journal:  Afr Health Sci       Date:  2013-06       Impact factor: 0.927

4.  Exacerbation of sickle cell disease itself as a cause of abnormal liver chemistry tests.

Authors:  Carmen M Stanca; Maria Isabel Fiel; Thomas D Schiano
Journal:  Dig Dis Sci       Date:  2006-12-15       Impact factor: 3.487

5.  THE PREVALENCE LIVER FUNCTION AND IMMUNOLOGIC STATUS OF CHILDREN WITH HIV AND HEPATITIS B VIRUS COINFECTION IN ENUGU, NIGERIA.

Authors:  Uleanya Nwachinemere Davidson; Nwokoye Ikenna Chidiebele; Emodi Ifeoma Josephine; Obidike Egbuna Olakunle; Ikefuna Anthony Nnaemeka; Eze Jude Chijioke; Ndu Ikenna Kingsley
Journal:  Afr J Infect Dis       Date:  2016-05-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.